Chenodiol is the non-proprietary name for chenodeoxycholic acid,
a naturally occurring human bile acid.
Chenodal (chenodiol tablets) is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result form a delay due to unsuccessful treatment. Safety of use beyond 24 months is not established. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones.
Clinical Trials Related to Chenodal (Chenodiol)
Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis [Recruiting]
OBJECTIVES: I. Assess the biosynthesis of cholesterol and cholestanol, and measure the
turnover of individual sterols and bile acids in patients with cerebrotendinous
xanthomatosis before and after a cholesterol- and cholestanol-free diet.
II. Assess the biosynthesis of cholesterol and cholestanol, and measure the turnover of
individual sterols and bile acids in these patients before and after lovastatin and
Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism [Recruiting]
The purpose of this study is to determine whether chenodeoxycholic acid decreases de novo
hepatic lipogenesis, hepatic fat content, hepatic triglyceride production and plasma
triglyceride concentrations and improves hepatic glucose metabolism in patients with the
metabolic syndrome, Familial Hypertriglyceridemia and Familial Combined Hyperlipidemia.
Study of Bile Acids in Patients With Peroxisomal Disorders [Not yet recruiting]
OBJECTIVES: I. Determine the effectiveness of oral bile acid therapy with cholic acid,
chenodeoxycholic acid, and ursodeoxycholic acid in patients with peroxisomal disorders
involving impaired primary bile acid synthesis.
II. Determine whether suppression of synthesis of atypical bile acids and enrichment of bile
acid pool with this regimen is effective in treating this patient population and improving
quality of life.
Effect of Bile Acids on GLP-1 Secretion [Not yet recruiting]
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis [Not yet recruiting]
The investigational drug, Obeticholica Acid (OCA) is a modified bile acid. Bile acids are
used by the body to help with digestion. It is hypothesized that regular treatment with OCA
will improve liver function in persons with Primary Biliary Cirrhosis (PBC).